We conclude that ProTrans, composed of WJMSCs, is safe in the tested dose range of 25–200 million cells when administered intravenously, and that a single treatment in adults recently diagnosed with type 1 diabetes with 200 million cells results in preservation of their endogenous insulin for at least a year. Here, INS is linked to type 1 diabetes mellitus.